# Table of contents

List of abbreviations 9

- Chapter 1 Introduction 11

**Part 1 – In vitro effect of mTOR pathway inhibitors on iNKT cells and regulatory T cells**

- Chapter 2 mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells 21

- Chapter 3 Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells 43

**Part 2 – The combination of everolimus and low-dose oral cyclophosphamide, a phase 1-2 clinical trial**

- Chapter 4 Study protocol of Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer 63

- Chapter 5 Immunological effects of everolimus in patients with metastatic renal cell cancer 79

- Chapter 6 Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma 99

- Chapter 7 The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial 127

- Chapter 8 Metronomic cyclophosphamide attenuates mTOR mediated expansion of regulatory T cells but does not improve survival in patients with metastatic renal cell cancer treated with everolimus 151

- Chapter 9 Summarizing discussion and future perspectives 171

- Chapter 10 Nederlandse samenvatting 181

Curriculum Vitae 189

List of publications 193

Dankwoord 197